Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065267 | PMC |
| http://dx.doi.org/10.1016/j.coviro.2021.03.008 | DOI Listing |
Publication Analysis
Top Keywords
vaccine platform
8
future considerations
4
considerations mrna-lipid
4
mrna-lipid nanoparticle
4
nanoparticle vaccine
4
platform vaccines
4
vaccines based
4
based mrna-containing
4
mrna-containing lipid
4
lipid nanoparticles
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!